57 related articles for article (PubMed ID: 22762138)
1. High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy.
Biermer M; Schlosser B; Fülöp B; van Bömmel F; Brodzinski A; Heyne R; Keller K; Sarrazin C; Berg T
J Viral Hepat; 2012 Aug; 19(8):547-53. PubMed ID: 22762138
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
3. Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy.
Rutter K; Scherzer TM; Beinhardt S; Kerschner H; Stättermayer AF; Hofer H; Popow-Kraupp T; Steindl-Munda P; Ferenci P
Antivir Ther; 2011; 16(8):1327-33. PubMed ID: 22155914
[TBL] [Abstract][Full Text] [Related]
4. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
Braun DL; Rauch A; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Metzner KJ; Böni J; Weber R; Fehr J
HIV Med; 2014 Nov; 15(10):625-30. PubMed ID: 24894776
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy.
Eurich D; Bahra M; Berg T; Boas-Knoop S; Biermer M; Neuhaus R; Neuhaus P; Neumann U
Exp Clin Transplant; 2011 Feb; 9(1):1-6. PubMed ID: 21605016
[TBL] [Abstract][Full Text] [Related]
8. Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period.
Bárcena R; Moreno A; Rodríguez-Gandía MA; Albillos A; Arocena C; Blesa C; García-Hoz F; Graus J; Nuño J; López-Hervás P; Gajate L; Martínez A; Bermejo T; Mateos ML; Del Campo S;
J Hepatol; 2013 Mar; 58(3):421-6. PubMed ID: 23073223
[TBL] [Abstract][Full Text] [Related]
9. Rescue therapy with intravenous silibinin in liver transplant recipients with recurrent HCV hepatitis - two case reports.
Socha Ł; Karpińska E; Jurczyk K; Laurans Ł; Bander D; Lachtara M; Wawrzynowicz-Syczewska M
Ann Transplant; 2014 Apr; 19():161-4. PubMed ID: 24714452
[TBL] [Abstract][Full Text] [Related]
10. Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial.
Rendina M; D'Amato M; Castellaneta A; Castellaneta NM; Brambilla N; Giacovelli G; Rovati L; Rizzi SF; Zappimbulso M; Bringiotti RS; Di Leo A
Transpl Int; 2014 Jul; 27(7):696-704. PubMed ID: 24673819
[TBL] [Abstract][Full Text] [Related]
11. Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.
Dahari H; Shteingart S; Gafanovich I; Cotler SJ; D'Amato M; Pohl RT; Weiss G; Ashkenazi YJ; Tichler T; Goldin E; Lurie Y
Liver Int; 2015 Feb; 35(2):289-94. PubMed ID: 25251042
[TBL] [Abstract][Full Text] [Related]
12. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period.
Mariño Z; Crespo G; D'Amato M; Brambilla N; Giacovelli G; Rovati L; Costa J; Navasa M; Forns X
J Hepatol; 2013 Mar; 58(3):415-20. PubMed ID: 23063567
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
DebRoy S; Hiraga N; Imamura M; Hayes CN; Akamatsu S; Canini L; Perelson AS; Pohl RT; Persiani S; Uprichard SL; Tateno C; Dahari H; Chayama K
J Viral Hepat; 2016 Sep; 23(9):708-17. PubMed ID: 27272497
[TBL] [Abstract][Full Text] [Related]
14. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.
Fried MW; Navarro VJ; Afdhal N; Belle SH; Wahed AS; Hawke RL; Doo E; Meyers CM; Reddy KR;
JAMA; 2012 Jul; 308(3):274-82. PubMed ID: 22797645
[TBL] [Abstract][Full Text] [Related]
15. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories.
Berkson BM
Med Klin (Munich); 1999 Oct; 94 Suppl 3():84-9. PubMed ID: 10554539
[TBL] [Abstract][Full Text] [Related]
16. Highly bioavailable silibinin nanoparticles inhibit HCV infection.
Liu CH; Lin CC; Hsu WC; Chung CY; Lin CC; Jassey A; Chang SP; Tai CJ; Tai CJ; Shields J; Richardson CD; Yen MH; Tyrrell DLJ; Lin LT
Gut; 2017 Oct; 66(10):1853-1861. PubMed ID: 27436270
[TBL] [Abstract][Full Text] [Related]
17. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.
Wagoner J; Morishima C; Graf TN; Oberlies NH; Teissier E; Pécheur EI; Tavis JE; Polyak SJ
PLoS One; 2011 Jan; 6(1):e16464. PubMed ID: 21297992
[TBL] [Abstract][Full Text] [Related]
18. Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.
Canini L; DebRoy S; Mariño Z; Conway JM; Crespo G; Navasa M; D'Amato M; Ferenci P; Cotler SJ; Forns X; Perelson AS; Dahari H
Antivir Ther; 2015; 20(2):149-55. PubMed ID: 24912382
[TBL] [Abstract][Full Text] [Related]
19. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.
Hawke RL; Schrieber SJ; Soule TA; Wen Z; Smith PC; Reddy KR; Wahed AS; Belle SH; Afdhal NH; Navarro VJ; Berman J; Liu QY; Doo E; Fried MW;
J Clin Pharmacol; 2010 Apr; 50(4):434-49. PubMed ID: 19841158
[TBL] [Abstract][Full Text] [Related]
20. Phytoliposome-Based Silibinin Delivery System as a Promising Strategy to Prevent Hepatitis C Virus Infection.
Ripoli M; Angelico R; Sacco P; Ceglie A; Mangia A
J Biomed Nanotechnol; 2016 Apr; 12(4):770-80. PubMed ID: 27301203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
